Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

Ellen F. T Yee; Robert E White; Glen H Murata; Christine Handanos; Richard M Hoffman

doi:10.1007/s11606-007-0291-4

Back

Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

Journal article

Open access

Peer reviewed

Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

Ellen F. T Yee, Robert E White, Glen H Murata, Christine Handanos and Richard M Hoffman

Journal of general internal medicine : JGIM, Vol.22(9), pp.1305-1310

09/2007

DOI: 10.1007/s11606-007-0291-4

PMCID: PMC2219777

PMID: 17634780

Files and links (1)

url

https://europepmc.org/articles/pmc2219777View

Published (Version of record) Open Access

Abstract

Background: The use of androgen deprivation therapy (ADT) for prostate cancer has increased substantially in recent years, exposing more men to potential treatment complications, including osteoporosis and fractures. Objective: To determine whether men treated with ADT for prostate cancer received osteoporosis screening, prevention, or treatment. Design: Cross-sectional observational study using a retrospective review of electronic medical records. Subjects: One hundred seventy-four patients with prostate cancer on ADT or status-post orchiectomy enrolled in primary care at the New Mexico Veterans Affairs Health Care System as of July 2005. Measurements: Patient demographics, tumor characteristics (Gleason score, stage, last PSA value, documented bone metastases), history of hip or vertebral fracture, osteoporosis risk factors (number of ADT shots, diabetes, smoking, heavy alcohol use or prescriptions for corticosteroids, thyroid hormone or dilantin). We defined recommended management as performing DXA scans or prescribing bisphosphonates, calcitonin, calcium or vitamin D. Results: Just 60 of 174 (34%) patients received recommended osteoporosis management based on DXA scans (13%) or treatment with oral or IV bisphosphonates (21%), calcitonin (1%), calcium (16%) or vitamin D (10%). On multivariate analysis, bone metastases, higher last PSA, and younger age at diagnosis were associated with recommended management, whereas Hispanic race/ethnicity was inversely associated. Conclusions: Most men treated with ADT for prostate cancer did not receive osteoporosis screening, prevention or treatment. Evidence for advanced cancer though not risk factors for osteoporosis or fracture-was associated with receiving osteoporosis management. Further research is needed to identify optimal strategies for screening, prevention, and treatment in this population.

Osteoporosis

Prostate Cancer

androgen deprivation therapy

screening

DXA scan

Original

prevention

Details

Title: Subtitle: Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy
Creators: Ellen F. T Yee - Department of Medicine, New Mexico Veterans Affairs Health Care System, Albuquerque, NM USA
Robert E White - Lovelace Clinic Foundation, Albuquerque, NM USA
Glen H Murata - Department of Medicine, New Mexico Veterans Affairs Health Care System, Albuquerque, NM USA
Christine Handanos - Department of Medicine, New Mexico Veterans Affairs Health Care System, Albuquerque, NM USA
Richard M Hoffman - Department of Medicine, New Mexico Veterans Affairs Health Care System, Albuquerque, NM USA
Resource Type: Journal article
Publication Details: Journal of general internal medicine : JGIM, Vol.22(9), pp.1305-1310
DOI: 10.1007/s11606-007-0291-4
PMID: 17634780
PMCID: PMC2219777
NLM abbreviation: J Gen Intern Med
ISSN: 0884-8734
eISSN: 1525-1497
Publisher: Springer-Verlag
Language: English
Date published: 09/2007
Academic Unit: Epidemiology; General Internal Medicine; Internal Medicine
Record Identifier: 9984094735502771

Metrics

10 Record Views

30 Times Cited - Web of Science